Although a switch from ETV to TDF therapy was adopted, this patient had advanced liver disease and did not show signs of sustained virologic response, as evidenced by a high viral load (3.98 log IU/mL) and the HBeAg+/anti-HB− phenotype. Here, GSTM1 is linked to liver disorder.